Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside (original) (raw)

Current Breast Cancer Reports, 2014

Abstract

A precise knowledge of cell-cycle machinery and its effect on tumorigenesis has led to the development of a large number of anticancer drugs targeting this pathway. In breast cancer research, the promising results of recent clinical trials of novel selective CDK-inhibitors, for example palbociclib, have generated high expectations for this field. This review gathers the results of the most recent clinical trials of CDK inhibitors for breast cancer, and outlines their potential as anticancer therapy.

Miriam Lobo hasn't uploaded this paper.

Let Miriam know you want this paper to be uploaded.

Ask for this paper to be uploaded.